期刊文献+

司来吉兰贴片处方的正交设计实验研究 被引量:3

Orthogonal Design of the Prescription of Selegiline Transdermal Patches
下载PDF
导出
摘要 目的确定司来吉兰贴片的处方及研究方法。方法通过正交设计试验研究确定司来吉兰贴片各组分的含量。结果司来吉兰经皮给药系统的最佳处方组成为:主药量为3%,促渗剂选用氮酮,含量为3%,增塑剂含量为15%,压敏胶含量为60%。背衬材料为涂铝膜的聚酯膜。结论司来吉兰适合制成经皮给药系统。正交设计实验是研究司来吉兰贴片处方的有效方法。 Objective To determine the prescription of selegiline transdermal patches.Methods The selegiline transdermal patches were prepared and the ingredient amount of selegiline transdermal patches was determined according to the orthogonal design.Results The best prescription of selegiline transdermal patches:3%selegiline,3%Azone,15%RS100,60%PSA.Conclusion Selegiline is suitable for the transdermal therapeutic systems.Orthogonal design of prescription was suitable to study selegiline transdermal patches.
出处 《中国医科大学学报》 CAS CSCD 北大核心 2010年第9期746-748,共3页 Journal of China Medical University
关键词 司来吉兰 贴片 正交设计 处方 selegiline patches orthogonal design prescription
  • 相关文献

参考文献5

  • 1赵鹏,张本恕,肖颖,孔屏,孙峰.盐酸司来吉兰治疗早期帕金森病的疗效观察[J].临床神经病学杂志,2005,18(4):306-307. 被引量:9
  • 2Chi-Un Pae, Hyun-kook Hm, Changsu Han,et al.Selegiline transdermal system:current awareness and promise.Progress in Neuro-Psychopharmacology and biological Psychiatry[J]. 2007,31(6): 1153- 1163.
  • 3J ia-You Fang, Chi-Feng Hung,Chen-Hsien Chi,et al. Transdennal perumeation of selegiline from hydrogel-membrane drug delivery systems.lnternatlonal Journal of Pharmaceutics [ J ]. 2009,380(1-2) : 33- 39.
  • 4Donald S.Robinson, Jay D. Amsterdam. The selejiline transdermal system in major depressive disorder:A systematic review of safety and tolerability.Journal Of Affective Disorders [J ]. 2008,105 ( 1-3 ) : 15- 23.
  • 5王刚,杜洪光,张恩宏,许丽丽,王桂蕾,王树明.促渗剂对司来吉兰贴片透皮性能的影响[J].中国药房,2008,19(7):511-513. 被引量:8

二级参考文献13

  • 1边佳明,赵维娟,许景峰.国外经皮给药系统的研究进展[J].中国药房,2005,16(14):1112-1114. 被引量:21
  • 2赵鹏,张本恕,肖颖,孔屏,孙峰.盐酸司来吉兰治疗早期帕金森病的疗效观察[J].临床神经病学杂志,2005,18(4):306-307. 被引量:9
  • 3Ebadi M,Sharma S,Shavali S,et al.Neuroprotective actions of selegiline[J].J Neurosci Res,2002, 67:285.
  • 4Larsen JP,Boas J,Erdal JE.Does selegiline modify the progression of early Parkinsons disease? Results from a five-year study. The Norwegian-Danish Study Group[J].Eur J Neurol,1999,6:539.
  • 5Palhagen S,Heinonen EH,Hagglund J,et al.Selegiline delays the onset of disability in de novo parkinsonian patients.Swedish Parkinson Study Group[J].Neurology,1998,51:520.
  • 6LeWitt P,Oakes D,Cui L.The need for levodopa as an end point of Parkinsons disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group[J].Mov Disord,1997,12:183.
  • 7Heinonen EH,Myllyla V.Safety of selegiline (deprenyl) in the treatment of Parkinsons disease[J].Drug Saf,1998,19:11.
  • 8Bhattacharya KF,Nouri S,Olanow CW,et al.Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension[J].Parkinsonism Relat Disord,2003,9:221.
  • 9Churchyard A, Mathias CJ, Boonkongchuen P, et al. Autonomic effects of selegiline:possible cardiovascular toxicity in Parkinsons disease[J].J Neurol Neurosurg Psychiatry,1997,63:228.
  • 10Bronaugh RL, Stewart RF, Congdon ER. Method for in vitro percutaneous absorption studies. Ⅱ. Animal models for human skin[J] . Toxcicol Appl Pharmacol , 1982, 62(3) :481.

共引文献13

同被引文献40

引证文献3

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部